Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$0 Mln
P/E Ratio
--
P/B Ratio
0
Industry P/E
--
Debt to Equity
0
ROE
-8.02 %
ROCE
--
Div. Yield
0 %
Book Value
--
EPS
-4.75
CFO
$-77.59 Mln
EBITDA
$-77.72 Mln
Net Profit
$-177.35 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Thermogenesis Holdings Inc (THMO)
| -50.00 | -- | -50.00 | -99.96 | -97.74 | -93.02 | -81.94 |
|
BSE Sensex*
| 0.39 | 6.40 | 1.96 | 7.69 | 10.43 | 20.75 | 10.61 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Thermogenesis Holdings Inc (THMO)
| -99.90 | -81.25 | -92.96 | -51.67 | -52.50 | 64.86 | -90.99 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 56.42 | 2,263.60 | -- | -0.83 | |
| 8.02 | 1,480.71 | 14.45 | 43 | |
| 1.97 | 118.37 | -- | -23.91 | |
| 3.95 | 474.17 | -- | -68.95 |
ThermoGenesis Holdings, Inc. develops, commercializes, and markets a range of automated technologies for cell-banking, cell-processing, and cell-based therapeutics in the United States, China, the United Arab Emirates, Vietnam, and internationally.... The company provides medical device products for automated cell processing. Its clinical bio-banking applications include AXP II Automated Cell Separation System, an automated fully closed cell separation system for isolating stem and progenitor cells from umbilical cord blood; and BioArchive Automated Cryopreservation System, an automated, robotic, liquid nitrogen controlled-rate-freezing and cryogenic storage system for cord blood samples and cell therapeutic products used in clinical applications. The company's point-of-care applications include XP Point-of-Care System, an automated, fully closed, sterile system that allows for the rapid and automated processing of autologous peripheral blood or bone marrow aspirate derived stem cells at the point-of-care, such as surgical centers or clinics; and PXP-1000 System, an automated, fully closed system that provides fast, reproducible separation of multiple cellular components from blood with minimal red blood cell contamination. Its cell processing products comprise X-Series products for general laboratory use, such as X-Lab for cell isolation, X-Wash System for cell washing and reformulation, and X-Mini for high efficiency small scale cell purification. The company also provides contract development and manufacturing services for cell and cell-based gene therapies. It markets and sells its medical device products through independent distributors, as well as direct to end-user customers. The company was formerly known as Cesca Therapeutics Inc. and changed its name to ThermoGenesis Holdings, Inc. in November 2019. ThermoGenesis Holdings, Inc. was incorporated in 1986 and is headquartered in Rancho Cordova, California. Read more
Chairman of the Board & CEO
Dr. Xiaochun Xu M.B.A., Ph.D.
Chairman of the Board & CEO
Dr. Xiaochun Xu M.B.A., Ph.D.
Headquarters
Rancho Cordova, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Thermogenesis Holdings Inc (THMO) stood at $ 18 Mln as on 31-Mar-24
The share price of Thermogenesis Holdings Inc (THMO) is $0.00 (NASDAQ) as of 05-Mar-2025 09:30 EDT. Thermogenesis Holdings Inc (THMO) has given a return of -97.74% in the last 3 years.
Thermogenesis Holdings Inc (THMO) has a market capitalisation of $ 0 Mln as on 05-Mar-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Thermogenesis Holdings Inc (THMO) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Thermogenesis Holdings Inc (THMO) and enter the required number of quantities and click on buy to purchase the shares of Thermogenesis Holdings Inc (THMO).
ThermoGenesis Holdings, Inc. develops, commercializes, and markets a range of automated technologies for cell-banking, cell-processing, and cell-based therapeutics in the United States, China, the United Arab Emirates, Vietnam, and internationally. The company provides medical device products for automated cell processing. Its clinical bio-banking applications include AXP II Automated Cell Separation System, an automated fully closed cell separation system for isolating stem and progenitor cells from umbilical cord blood; and BioArchive Automated Cryopreservation System, an automated, robotic, liquid nitrogen controlled-rate-freezing and cryogenic storage system for cord blood samples and cell therapeutic products used in clinical applications. The company's point-of-care applications include XP Point-of-Care System, an automated, fully closed, sterile system that allows for the rapid and automated processing of autologous peripheral blood or bone marrow aspirate derived stem cells at the point-of-care, such as surgical centers or clinics; and PXP-1000 System, an automated, fully closed system that provides fast, reproducible separation of multiple cellular components from blood with minimal red blood cell contamination. Its cell processing products comprise X-Series products for general laboratory use, such as X-Lab for cell isolation, X-Wash System for cell washing and reformulation, and X-Mini for high efficiency small scale cell purification. The company also provides contract development and manufacturing services for cell and cell-based gene therapies. It markets and sells its medical device products through independent distributors, as well as direct to end-user customers. The company was formerly known as Cesca Therapeutics Inc. and changed its name to ThermoGenesis Holdings, Inc. in November 2019. ThermoGenesis Holdings, Inc. was incorporated in 1986 and is headquartered in Rancho Cordova, California.
The CEO & director of Dr. Xiaochun Xu M.B.A., Ph.D.. is Thermogenesis Holdings Inc (THMO), and CFO & Sr. VP is Dr. Xiaochun Xu M.B.A., Ph.D..
There is no promoter pledging in Thermogenesis Holdings Inc (THMO).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
232
|
|
|
155
|
|
|
53
|
|
|
12
|
| Thermogenesis Holdings Inc (THMO) | Ratios |
|---|---|
|
Return on equity(%)
|
-493.79
|
|
Operating margin(%)
|
-40.68
|
|
Net Margin(%)
|
-153.43
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Thermogenesis Holdings Inc (THMO) was $-2 Mln.
$0.00
(
